A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-03-04
Target enrollment:
Participant gender:
Summary
The main aim of this study is to determine safety and tolerability of modakafusp alfa given
together with daratumumab to find out the best treatment dose. Another aim of this study is
to learn more about the characteristics of modakafusp alfa.